166 related articles for article (PubMed ID: 28275912)
1. Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.
Arruga F; Deaglio S
Handb Exp Pharmacol; 2018; 249():203-229. PubMed ID: 28275912
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies in CLL: mechanisms of resistance and strategies for management.
Woyach JA; Johnson AJ
Blood; 2015 Jul; 126(4):471-7. PubMed ID: 26065659
[TBL] [Abstract][Full Text] [Related]
3. Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options.
Audrito V; Vaisitti T; Serra S; Bologna C; Brusa D; Malavasi F; Deaglio S
Cancer Lett; 2013 Jan; 328(1):27-35. PubMed ID: 22910767
[TBL] [Abstract][Full Text] [Related]
4. The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.
Jacobs RW; Awan FT; Leslie LA; Usmani SZ; Ghosh N
Expert Rev Hematol; 2016 Dec; 9(12):1177-1187. PubMed ID: 27791448
[TBL] [Abstract][Full Text] [Related]
5. Chronic lymphocytic leukemia.
Byrd JC; Stilgenbauer S; Flinn IW
Hematology Am Soc Hematol Educ Program; 2004; ():163-83. PubMed ID: 15561682
[TBL] [Abstract][Full Text] [Related]
6. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
7. Signal transduction inhibitors in chronic lymphocytic leukemia.
Ma S; Rosen ST
Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
[TBL] [Abstract][Full Text] [Related]
8. Novel approaches to modulate apoptosis resistance: basic and clinical implications in the treatment of chronic lymphocytic leukemia (CLL).
Masood A; Shahshahan MA; Jazirehi AR
Curr Drug Deliv; 2012 Jan; 9(1):30-40. PubMed ID: 22023214
[TBL] [Abstract][Full Text] [Related]
9. Using the biology of chronic lymphocytic leukemia to choose treatment.
Hillmen P
Hematology Am Soc Hematol Educ Program; 2011; 2011():104-9. PubMed ID: 22160020
[TBL] [Abstract][Full Text] [Related]
10. Improving treatment for patients with chronic lymphocytic leukemia.
Shanafelt TD
Hematology; 2012 Apr; 17 Suppl 1():S133-6. PubMed ID: 22507801
[TBL] [Abstract][Full Text] [Related]
11. Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.
Lin TS
Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S137-43. PubMed ID: 18952544
[TBL] [Abstract][Full Text] [Related]
12. Emerging therapies for refractory chronic lymphocytic leukemia.
Kutsch N; Hallek M; Eichhorst B
Leuk Lymphoma; 2015 Feb; 56(2):285-92. PubMed ID: 24766469
[TBL] [Abstract][Full Text] [Related]
13. Update on signal inhibitors in chronic lymphocytic leukemia.
Boddu P; Jain N
Clin Adv Hematol Oncol; 2018 Apr; 16(4):279-288. PubMed ID: 29742083
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.
Maffei R; Colaci E; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
Crit Rev Oncol Hematol; 2016 Jan; 97():291-302. PubMed ID: 26454471
[TBL] [Abstract][Full Text] [Related]
16. Treatment options in chronic lymphocytic leukemia.
Montserrat E
Hematol J; 2004; 5 Suppl 1():S2-9. PubMed ID: 15079148
[TBL] [Abstract][Full Text] [Related]
17. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.
Kubuschok B; Trepel M
Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631
[TBL] [Abstract][Full Text] [Related]
18. Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms.
Zhang W; Pelicano H; Yin R; Zeng J; Wen T; Ding L; Huang R
Mol Med Rep; 2015 Nov; 12(5):7374-88. PubMed ID: 26458979
[TBL] [Abstract][Full Text] [Related]
19. Potential new agents for chronic lymphocytic leukemia treatment.
Kiliańska ZM; Rogalińska M
Anticancer Agents Med Chem; 2010 Nov; 10(9):666-82. PubMed ID: 21235440
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy for chronic lymphocytic leukemia: current status and future directions.
Arnason JE; Brown JR
Drugs; 2015 Feb; 75(2):143-55. PubMed ID: 25619739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
